XML 46 R34.htm IDEA: XBRL DOCUMENT v3.25.1
Fair Value of Financial Instruments (Tables)
9 Months Ended
Mar. 31, 2025
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value
The following table summarizes the valuation of the Company’s remaining assets and liabilities measured at fair value on a recurring basis at March 31, 2025:
TotalQuoted
prices in
active
markets
(Level 1)
Significant
other
observable
inputs
(Level 2)
Significant
unobservable
inputs
(Level 3)
 (in thousands)
Assets:
Deferred compensation plan investments, current and non-current$30,110 $30,110 $ $ 
Forward foreign currency exchange contracts17  17  
Interest rate swap agreement1,046  1,046  
Foreign currency hedge16  16  
Total assets at fair value$31,189 $30,110 $1,079 $ 
Liabilities:
Deferred compensation plan investments, current and non-current$30,110 $30,110 $ $ 
Liability for contingent consideration, current and non-current19,247   19,247 
Total liabilities at fair value$49,357 $30,110 $ $19,247 

The following table summarizes the valuation of the Company’s remaining assets and liabilities measured at fair value on a recurring basis at June 30, 2024:
TotalQuoted
prices in
active
markets
(Level 1)
Significant
other
observable
inputs
(Level 2)
Significant
unobservable
inputs
(Level 3)
 (in thousands)
Assets:
Deferred compensation plan investments, current and non-current $31,014 $31,014 $— $— 
Interest rate swap agreement2,698 — 2,698 — 
Foreign currency hedge345 — 345 — 
Total assets at fair value$34,057 $31,014 $3,043 $— 
Liabilities:
Deferred compensation plan investments, current and non-current$31,014 $31,014 $— $— 
Forward foreign currency exchange contracts12 — 12 — 
Total liabilities at fair value$31,026 $31,014 $12 $— 
Schedule of Changes in Fair Value of Contingent Considerations
The following tables represent the Company's contingent consideration liabilities at fair value at March 31, 2025:
Quarter ended March 31, 2025
 Specialty Technology SolutionsIntelisys & AdvisoryTotal
 (in thousands)
Fair value at beginning of period$7,973 $10,370 $18,343 
Change in fair value of contingent consideration94 810 904 
Fair value at end of period$8,067 $11,180 $19,247 
Nine months ended March 31, 2025
Specialty Technology SolutionsIntelisys & AdvisoryTotal
(in thousands)
Fair value at beginning of period$ $ $ 
Issuance of contingent consideration7,500 9,700 17,200 
Change in fair value of contingent consideration567 1,480 2,047 
Fair value at end of period$8,067 $11,180 $19,247 
Valuation techniques and significant observable inputs used in recurring Level 3 fair value measurements for the Company's contingent consideration liabilities related to Advantix and Resourcive at March 31, 2025 were as follows.
AcquisitionReporting PeriodValuation TechniqueSignificant Unobservable InputsWeighted Average Rates
AdvantixMarch 31, 2025Discounted cash flowAdjusted EBITDA risk premium15.0 %
Adjusted EBITDA growth rate28.1 %
ResourciveMarch 31, 2025Monte CarloAdjusted EBITDA risk premium12.9 %
Simulated commission growth percentage15.2 %